OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Ematobase.it
Reumabase.it

Search results for "Lapatinib"

A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...


A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...


A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...


Paclitaxel ( Taxol ) is one of the most commonly used chemotherapies in breast cancer. Therefore, the evaluation of Lapatinib ( Tykerb ) in combination with this treatment is of high importance. A ...


One-third of women with HER2-positive metastatic breast cancer currently develop brain metastases. Once the disease advances to this stage, overall disease prognosis is poor with the average one-yea ...


Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the grow ...


Use of Lapatinib ( Tykerb ) to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While ...


Lapatinib ( Tykerb ) could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. The findings of this phase ...


The College of American Pathologists ( CAP ) and the American Society of Clinical Oncology ( ASCO ) have issued a joint, updated guideline aimed at improving the accuracy and reporting of human epider ...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset of patients wit ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kadcyla, 100 mg and 160 mg, ...


Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. Resear ...


Researchers conducted a phase IIb randomized trial of preoperative chemotherapy ( CT ) plus Trastuzumab ( T ), Lapatinib ( L ), or the combination of Trastuzumab plus Lapatinib in HER2+ operable breas ...


Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs Lapatinib /( Tyverb; Tykerb ) and Trastuzumab ( Herceptin ) before surgery ...